Humana Inc. Common Stock (HUM)
Stock · NYSE · Health Care
$413.16as of 10/16/2026
Price chart
Active signals
HUM Signal Track Record
How signals performed across all stocks →What HUM's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 34 | +1.0% | 53% | October 8, 2026 |
| Bollinger Band Breakout | 24 | -1.8% | 46% | October 9, 2026 |
| Bollinger Band Breakdown | 21 | -0.2% | 48% | September 22, 2026 |
| 200-Day Moving Average TouchActive now | 20 | +1.1% | 50% | April 30, 2026 |
| Any 20-session window (baseline) | -0.1% | 50% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About HUM
Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. The Insurance segment offers individual Medicare Advantage products, including health insurance benefits, including wellness programs, chronic care management, and care coordination; individual Medicare stand-alone prescription drug products (PDP); group Medicare advantage and Med…
- Sector
- Health Care
- Industry
- Medical Specialities
- Employees
- 67,060
- Website
- www.humana.com/
Fundamentals
- 1-day range
- $410.51$442.89
- Market cap
- $44.10B
- P/E (trailing)
- 39.25
- P/E (forward)
- 25.34
- EPS (trailing)
- $10.56
- Dividend yield
- 0.68%
- Beta
- 0.68
- Avg. volume
- 1.32M
- Ex-dividend date
- October 30, 2026
- Dividend pay date
- November 27, 2026
How Humana Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 19, 2026 · via SEC EDGAR / Finnhub
Forecasts
24 analyst ratings
Humana Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- HUMHumana Inc. Common Stock$413.16▼ 4.41%Market cap $44.10BP/E 39.25$163.11$456.5
- NTRANatera Inc. Common Stock$393.44▼ 2.80%Market cap $38.01BP/E —$170.82$437.41
- CNCCentene Corporation Common Stock$69.16▼ 1.91%Market cap $31.71BP/E —$31.63$70.37
- ILMNIllumina Inc. Common Stock$262.54▼ 2.01%Market cap $29.25BP/E 48.62$88$309.35
- DGXQuest Diagnostics Incorporated Common Stock$235▼ 1.74%Market cap $26.32BP/E 24.67$171.18$248.84
- LHLabcorp Holdings Inc. Common Stock$317.95▼ 2.19%Market cap $25.96BP/E 25.55$244.52$341.8
- GHGuardant Health Inc. Common Stock$158.6▼ 4.39%Market cap $21.15BP/E —$61$191.05
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| HUM Humana Inc. Common Stock | $44.10B | 39.25 | $413.16 | ▼ 4.41% | $163.11$456.5 |
| NTRA Natera Inc. Common Stock | $38.01B | — | $393.44 | ▼ 2.80% | $170.82$437.41 |
| CNC Centene Corporation Common Stock | $31.71B | — | $69.16 | ▼ 1.91% | $31.63$70.37 |
| ILMN Illumina Inc. Common Stock | $29.25B | 48.62 | $262.54 | ▼ 2.01% | $88$309.35 |
| DGX Quest Diagnostics Incorporated Common Stock | $26.32B | 24.67 | $235 | ▼ 1.74% | $171.18$248.84 |
| LH Labcorp Holdings Inc. Common Stock | $25.96B | 25.55 | $317.95 | ▼ 2.19% | $244.52$341.8 |
| GH Guardant Health Inc. Common Stock | $21.15B | — | $158.6 | ▼ 4.39% | $61$191.05 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Humana (HUM) Deepens MA Neuromodulation Coverage: A Clue to Its Margin Recovery Strategy?Yahoo · 10/10/2026
- Humana (HUM) Stock Trades Up, Here Is WhyYahoo · 10/9/2026
- Sector Update: Healthcare Stocks Gain Late AfternoonYahoo · 10/9/2026
- Humana Shares Surge Following Significant Medicare Advantage Star Ratings ImprovementYahoo · 10/9/2026
- Discover which S&P500 stocks are making waves on Friday.ChartMill · 10/9/2026
- Sector Update: Healthcare Stocks Gain Friday AfternoonYahoo · 10/9/2026
- Humana Leads Managed Care Peers in 2027 Medicare Advantage Star Ratings, Deutsche Bank SaysYahoo · 10/9/2026
- Humana Surges On 2027 CMS Ratings, Technical Breakout, Shares Fairly PricedSeekingAlpha · 10/9/2026
Insider Activity
Insider Actions →- Kurt J. Hilzinger · September 30, 2026 · Grant238 @ $384.91
- Nundy Shantanu · September 1, 2026 · Grant2.5K
- Paul John Smith · August 1, 2026 · Grant544
- Frederick John Crawford · August 1, 2026 · Grant544
- Kurt J. Hilzinger · June 30, 2026 · Grant233 @ $392.32
- Robert Stuart Field · May 1, 2026 · Grant852
- Aaron Martin · May 1, 2026 · Grant8.2K
- Japan Mehta · May 1, 2026 · Grant9.4K
- David Dintenfass · May 1, 2026 · Grant11.3K
- James A. Rechtin · May 1, 2026 · Grant35.6K
- Sanjay K. Shetty · May 1, 2026 · Grant9.9K
- Michelle A. O'Hara · May 1, 2026 · Grant10.5K
- Joseph C. Ventura · May 1, 2026 · Grant10.3K
- Celeste Mellet · May 1, 2026 · Grant15.4K
Institutional Ownership
March 31, 2026
- Total shares held
- 112.71M
- Total value held
- $19.22B
- Institutional holders
- 774
- Unknown11.38M
- Unknown10.20M
- Unknown7.84M
- Unknown5.47M
- Unknown5.45M
- Unknown4.48M
- Unknown3.73M
- Unknown3.33M
- Unknown2.97M
- Unknown2.86M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Humana to drop 37 PPOs for 2027 Medicare Advantage plans
Humana announced it will discontinue 37 Preferred Provider Organization (PPO) plans for the 2027 Medicare Advantage enrollment period. The company noted that affected members may qualify for a Medigap open enrollment window without health questions. This structural change impacts the company's product lineup and member retention strategies for the upcoming year.
Humana to drop 37 PPOs for 2027 Medicare Advantage plans. Humana announced it will discontinue 37 Preferred Provider Organization (PPO) plans for the 2027 Medicare Advantage enrollment period. The company noted that affected members may qualify for a Medigap open enrollment window without health questions. This structural change impacts the company's product lineup and member retention strategies for the upcoming year.